Regulatory Update

S-Docs Wins FedRAMP Attestation for Salesforce Government Cloud

United States – October 12, 2026 -- S-Docs, a document automation and e-Signature provider, has received FedRAMP attestation, opening a path to expand with U.S. government agencies and the wider public sector.

FedRAMP status targets security-sensitive public-sector buyers

FedRAMP is the U.S. government's standardized framework for validating the security of cloud platforms that process sensitive, data-heavy workloads. It lets agencies adopt advanced cloud and AI capabilities with speed and confidence.

S-Docs says the attestation lets it grow its footprint with U.S. government agencies and the public sector. It also lays the groundwork for partnerships with other security-conscious organizations.

S-Docs Wins SOC 2 Type II Compliance for HubSpot Product

New York City – October 12, 2026 -- S-Docs has achieved SOC 2 Type II compliance for its HubSpot product, passing an independent audit of how it safeguards customer data over an extended period.

The assessment, developed by the American Institute of Certified Public Accountants (AICPA), tests whether security controls are well-designed and consistently operating in practice. It draws on the AICPA's Trust Services Criteria: security, availability, processing integrity, confidentiality and privacy.

Audit covered six control areas at S-Docs

The audit included control testing and operational analysis across security monitoring, access controls, incident response, disaster recovery, business continuity and internal risk management. S-Docs says the results confirm repeatable security practices in its day-to-day operations.

National Grid Shifts to Bay Sharing for Connections up to 450 MW

Image
National Grid Shifts to Bay Sharing for Connections up to 450 MW

United Kingdom – October 12, 2026 -- National Grid Electricity Transmission is moving new transmission connection applicants toward shared "bay sharing" arrangements that let multiple customers with requirements of up to 450 MW connect through common facilities. The shift is part of Phase 2 of Connections Reform and aims to use existing assets more efficiently and reduce the need for dedicated infrastructure.

Three shared connection products are now on offer

Grid Parks connect up to three customers through a shared transformer and lower-voltage infrastructure. They suit smaller customers with requirements up to approximately 57 MW and are already used across the transmission network.

Super Grid Parks use higher-voltage infrastructure for larger customers or more customers, with projects of around 150 MW as the target. They are aimed at new substations where future customer growth can be planned.

XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Drug

Image
XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Drug

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX) plans to submit an Investigational New Drug application to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program, and estimates the program addresses a US$700M annual market opportunity.

XORTX targets an NDA filing in about one year, contingent on funding

The IND describes the company's clinical development plan for XORLOTM, its proprietary oxypurinol formulation, and its intention to file a New Drug Application after completing the two-part XRX-OXY-102 clinical trial. The trial is designed to characterize the pharmacokinetics and efficacy information the FDA needs to evaluate a future NDA.

XORTX Plans Health Canada Trial Filing for Gout Drug XRx-026

Image
XORTX Plans Health Canada Trial Filing for Gout Drug XRx-026

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX) plans to run the first part of its two-part XRX-OXY-102 gout study in Canada, a move it expects to speed delivery of the clinical data needed for a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).

XORTX prepares Health Canada filing in parallel with FDA track

The company has outlined an anticipated Clinical Trial Application (CTA) to Health Canada for its XRx-026 gout program. The study evaluates XORLO, XORTX's proprietary formulation of oxypurinol, a xanthine oxidase inhibitor. Drug development teams have been preparing the CTA in parallel with the planned FDA NDA submission.

I&M Seeks Approval for 1,520 MW Gas Plant at Rockport, Indiana

Image
I&M Seeks Approval for 1,520 MW Gas Plant at Rockport, Indiana

Fort Wayne – October 12, 2026 -- Indiana Michigan Power (I&M) has asked the Indiana Utility Regulatory Commission (IURC) to approve a 1,520 megawatt (MW) natural gas combined cycle plant at its Rockport site, one of the largest utility construction projects in Indiana.

I&M expects power demand in its Indiana service area to more than double by the early 2030s. The new Rockport Energy Center is meant to add generation capacity to meet that load.

I&M targets summer 2030 start-up, with an IURC ruling expected in early 2027

I&M filed for a certificate of public convenience and necessity (CPCN). The filing details the construction timeline, the allocation of construction and operating costs, regional transmission capacity and environmental factors.

The company anticipates an IURC decision in early 2027. Construction would begin in 2027, and the plant is expected to be operational in summer 2030.

AnX Robotica: ProScan Cut Capsule Review Time 88.6% in FDA Filing

Image
AnX Robotica: ProScan Cut Capsule Review Time 88.6% in FDA Filing

Plano, Texas – October 11, 2026 -- AnX Robotica said its NaviCam ProScan AI reading technology cut mean small-bowel capsule endoscopy review time by 88.6% in the study underlying its FDA De Novo clearance, against a 24.7% reduction reported for a competing AI-assisted platform cleared on September 25, 2026.

FDA names ProScan as primary predicate for the new clearance

The FDA's 510(k) clearance K254230 identifies NaviCam ProScan (DEN230027) as its primary predicate device. Both products assist clinicians reviewing small-bowel capsule endoscopy studies. ProScan received its De Novo decision on December 12, 2023.

NYSE American Gives IT Tech Packaging Until April 2027 to Cure Filings

Baoding – – October 09, 2026 -- NYSE Regulation has granted IT Tech Packaging (NYSE American: ITP) a plan period through April 15, 2027 to file three overdue SEC reports, keeping the paper maker listed while it works to restore compliance.

NYSE Regulation accepted ITP's extension request on October 7, 2026

ITP submitted the request on October 1, 2026. Section 1007 of the NYSE American Company Guide requires one when a company cannot cure a filing delinquency within the first six months of the maximum 12-month cure period. NYSE Regulation's letter of October 7 accepted the request and covers the delayed filings plus any subsequently delayed filings.

SmallRig Wins Final Patent Ruling Against Neewer in China Court

Shenzhen, China – – October 08, 2026 -- The High People's Court of Guangdong Province has issued a final, legally binding judgment in favor of Shenzhen Leqi Innovation Co., Ltd., the company behind imaging accessories brand SmallRig, in a design patent infringement case against Shenzhen Neewer Technology Co., Ltd. and Shenzhen Xing Ying Da Industry Co., Ltd.

Court dismisses Neewer's appeal and upholds full damages award

The court ruled that the accused side handle products fall within the scope of protection of Leqi Innovation's design patent, dismissing Neewer Technology's appeal and affirming the trial court's judgment in its entirety. The two defendants were ordered to cease manufacturing and selling the infringing side handles, destroy remaining inventory and related promotional materials, bear all court costs, and pay damages to Leqi Innovation. The damages have been paid in full.

24X Expands Warrant Incentive Program Ahead of December Launch

Stamford, Conn. – October 08, 2026 -- 24X National Exchange LLC has filed a proposed rule change with the U.S. Securities and Exchange Commission to expand its warrant performance incentive program, adding equity worth 22.25% of parent company 24X US Holdings LLC on a fully diluted basis for participating broker-dealers.

24X adds 22.25% in new equity and extends program through June 2028

The original program, running through December 31, 2027, offered non-voting equity equal to 10% of 24X US Holdings on a fully diluted basis. The newly filed expansion (SR-24X-2026-26) can be earned starting in 2027 and across two additional quarterly measurement periods in 2028, pushing the program's end date to June 30, 2028.